Omega Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
140 1st St Ste 501, Cambridge, Massachus...Phone Number
(617) 949-4360Website
www.omegatherapeutics.comRevenue
$6.3 MillionStock Symbol
OMGAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Omega Therapeutics
Omega Therapeutics is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines. Established in 2017, Omega Therapeutics is headquartered in Massachusetts, United States.Explore more
Omega Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Omega Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Omega Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Omega Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Omega Therapeutics recently announced quarterly report
Click to see if Omega Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Omega Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Omega Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Omega Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Omega Therapeutics
Recommended Actions
Find VP level buyers at Omega Therapeutics
Find 3 more new buyers
Compare Similar Companies to Omega Therapeutics
Compare insights from companies similar to Omega Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Omega Therapeutics
$6.3M
51-200
Public
$211M
2017
SS
Sivakesava SakhamuriSenior VP, Quality Head of Technical Operations
Company Profile Activity
Activity Insights
Omega Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Omega Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Omega Therapeutics.
Omega Therapeutics financials insights
Gather financial insights about Omega Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Unspecified
$85M
2021
Series C
$126M
Omega Therapeutics Tech Stack
A closer look at the technologies used by Omega Therapeutics
See more technologies
Most Recent Scoops
Layoffs
Layoffs
Pain Point
Pain Point, Asset Management, Bankruptcy
Earnings
Earnings, Finance
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Omega Therapeutics News & Media
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega’s approach to precision epigenomic control and the ability of OTX-2002 to controllably regulate the historically undruggablOmega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company’s executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in bOmega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Omega Therapeutics
Sign Up For FreeTo access detailed company insights
Omega Therapeutics is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines. Established in 2017, Omega Therapeutics is headquartered in Massachusetts, United States.... Read More
